english.prescrire.org > Spotlight > 100 most recent

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Oral contraception: estetrol + drospirenone (Drovelis°), a combination to avoid

Yet another combined oral contraceptive has been marketed in Europe: a combination of estetrol and drospirenone (Drovelis°). But it is probably better to avoid the combination of an insufficiently evaluated oestrogen and a progestogen with worrying adverse effects.
1 October 2022

Antibiotic resistance: a growing threat

Action is needed on various fronts to tackle microbial resistance, including reducing the use of antibiotics in intensive animal-rearing, rationalising their use in humans, and developing antibiotics with new mechanisms of action.
1 October 2022

Oral use of injectable drugs: uncertain efficacy and known risks

Healthcare professionals sometimes administer an injectable form of a drug by mouth when no suitable oral liquid form exists. It is a risky and often ineffective practice. There is an old saying in France that if a substance can be injected it can also be swallowed, but despite its appeal, this idea is misleading and dangerous.
1 October 2022

Mycophenolic acid and pregnancy: genotoxicity, malformations, spontaneous abortions

FEATURED REVIEW Mycophenolic acid is used as an immunosuppressant to prevent graft rejection after certain types of organ transplant. What is known as of mid-2022 about the possible harms to children of in-utero exposure to this drug?
Full review (4 pages) available for download by subscribers.
1 September 2022

In the September issue of Prescrire International: late-onset neutropenia linked to rituximab (Mabthera° or other brands)

FREE DOWNLOAD Among 104 reports to French regional pharmacovigilance centres involving severe late-onset neutropenia linked to rituximab, the time to onset varied from 1.5 to 15 months after the last dose. These cases of neutropenia expose patients to a risk of serious infections.
Full text available for free download.
1 September 2022

Moderate use of medicines

 Editorial  There are many reasons for moderate use of medicines. First and foremost, to reduce the risk of adverse effects and drug interactions. But also to use drugs for what they are: just one of several therapeutic options, not the answer to everything.
1 September 2022

Imiquimod 3.75% cream (Zyclara°) in actinic keratosis

In Focus An imiquimod 3.75% cream came onto the French market in 2021, under the brand name Zyclara°. It has a lower dose strength than Aldara° (3.75% instead of 5%), and it is applied daily for two 14-day periods. What do Prescrire's editors make of this new product?
1 September 2022

How long should one wait after stopping a drug before starting a pregnancy?

Some key principles to help answer this question without relying solely on the summary of product characteristics.
1 September 2022

Prescrire's annual review of drug packaging: choose high-quality packaging for safer health care

A drug's packaging contributes greatly to the quality of care patients receive, to patients' safety, and to the safety of those around them. There were a few signs of progress in 2021, but packaging is still too often neglected by drug companies and regulators.
1 September 2022

The European Implementing Regulation on Pharmacovigilance Activities

The proposed revision is a step towards greater independence from drug companies and better control of the quality and disclosure of data, but additional improvements are needed.
1 September 2022

1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90